

COMPANY REGISTRATION NUMBER: 00190705

AAH Limited
Financial Statements
31 March 2020



AAH Limited

Financial Statements

Year ended 31 March 2020

Contents	Page
Strategic report	1
Directors' report	3
Independent auditor's report to the members	7
Statement of income and retained earnings	8
Statement of financial position	11
Notes to the financial statements	12

AAH Limited

Strategic Report

Year ended 31 March 2020

The directors present their strategic report for the year ended 31 March 2020.

Principal activities and business review

The company's principal activity is that of an investment company of which its subsidiaries are involved in the wholesaling and retailing of pharmaceutical products.

The pharmaceutical wholesale and retail markets continue to be highly challenging. With the strategies adopted by the subsidiaries the directors believe the performance of the company's investments in the year was in line with expectations.

Throughout the year the Department of Health continued to make various reductions to pharmacy remuneration in England and these have had an adverse impact on the performance of the Lloyds pharmacy business. Actions are ongoing to mitigate the effect of the cuts; the business remains diligent and accordingly closed and sold a number of pharmacy locations during the financial year.

Principal risks and uncertainties

The key business risk is the performance of the company's investments. The management of the divisions and the execution of their strategies are subject to a number of key risks, namely competition, employee retention, supply chain, government action and financial risk including credit, liquidity, foreign currency and interest rate risk. Risks are formally reviewed by the board of each division and appropriate processes are put in place to monitor and mitigate them.

Financial risk management

The financial risks are managed by the immediate parent undertaking Admenta UK Limited. The management of these risks are discussed in the Admenta UK Limited financial statements.

Key performance indicators (KPIs)

Due to the company's principal activity as an investment holding company, the company's directors see net assets/(liabilities) as the key KPI. Net assets have decreased from £82.4m as at 31 March 2019 to £26.2m as at 31 March 2020. This is driven by the current year impairments arising from net debt held at subsidiary companies, increased uncertainty, and reduction in estimated future net cash inflows.

AAH Limited

Strategic Report

Year ended 31 March 2020 *(continued)*

Statement by the directors on the performance of their statutory duties in accordance with s172(1) of the Companies Act 2006


The success of our business is dependent on the support of all of relevant stakeholders. Building positive relationships with stakeholders that share our values is important to us. Working together towards shared goals assists us in delivering long-term sustainable success supporting the UK health care system. Further detail on how the Board has considered and has regard to the interests of its stakeholders, including shareholders is set out in the detail below.

Shareholders

As a subsidiary of McKesson Corporation an internal global policy framework ensures that the way in which we operate is fully aligned with the expectations of our shareholders. McKesson Corporation manages external shareholder relationships on behalf of the Company. Directors receive information in a range of different formats which includes information relevant to section 172 matters when making relevant decisions. For example, each year we make an assessment of the strength of the Company's balance sheet and future prospects relative to market uncertainties and make decisions about the payment of dividends.

As the principle activity of the company is to act as a holding company for certain UK subsidiaries, the Company has no commercial business, and no employees, suppliers or customers other than other McKesson Corporation entities during the period and as such the breadth of stakeholder considerations that would often apply in operating or commercial trading companies have generally not applied to the decisions made by the directors.

This report was approved by the board of directors on 2 June 2021 and signed on behalf of the board by:

DocuSigned by:

BDB7F99981984A8...

C Keen
Director

Registered office:
Sapphire Court
Walsgrave Triangle
Coventry
CV2 2TX

AAH Limited

Directors' Report

Year ended 31 March 2020

The directors present their annual report and the audited financial statements of the company for the year ended 31 March 2020.

Directors

The directors who served the company during the year and up to the date of the financial statements were as follows:

J Davies	
T M Anderson	
C Keen	(Appointed 25 November 2019)
N Swift	(Resigned 16 August 2019)
C McDermott	(Resigned 16 October 2019)
M Hilger	(Resigned 25 November 2019)

Dividends

No dividend was paid during the year (2019: £nil). No dividends were declared after year-end.

Directors' Responsibility under Section 172 and Statement of engagement with suppliers, customers and others in a business relationship with the Company

The Directors welcome the requirements under Section 172 and Sch. 7.11B(1) to Companies Act 2006. Comments on how the Directors have had a regard for the interests of various stakeholders whilst making key decisions are contained on pages 1-2 in the Strategic Report.

Energy and Carbon Regulations

In the opinion of the Directors, the company has consumed less than 40,000kWh of energy during the financial year and therefore there is no further information required to be disclosed.

Disclosure of information in the strategic report

The company has chosen in accordance with section 414C(11) of the Companies Act 2006 (Strategic Report and Directors' Report) Regulations 2013 to set out in the company's strategic report information required by schedule 7 of the Large and Medium-sized Companies and Groups (Accounts and Reports) Regulations 2008.

The strategic report on page 1 makes reference to the following: principal activities and business review, principal risks and uncertainties, financial risk management and key performance indicators (KPIs).

Going concern

The directors have received confirmation from the ultimate parent company that intergroup debt will continue to be made available at levels sufficient to allow the company to meet its liabilities as they fall due for a period not less than 12 months. The directors have satisfied themselves that the ultimate parent company has the necessary financial resources to provide this support during this period, should it be required. Therefore, the directors have a reasonable expectation that the company has adequate resources internally and through its association with the McKesson Corp, to continue in operational existence for the foreseeable future. As such, the going concern basis has been adopted in preparing the annual report and financial statements.

Further details regarding the adoption of the going concern basis can be found in the Statement of accounting policies in the financial statements.

AAH Limited

Directors' Report *(continued)*

Year ended 31 March 2020

Future developments

Given the straightforward nature of the business, there are no future developments to note. The company will continue to act as a holding company going forward.

United Kingdom trading relationship with the European Union

The United Kingdom ("UK") entered into a trading arrangement with the European Union ("EU") on December 31st, 2020. Under this arrangement, goods trade costs are likely to increase due to customs compliance requirements, potential border delays, rules of origin requirements and the need for products to satisfy different regulations and standards in the UK than the EU. The principal risks we face are around ensuring uninterrupted supply of pharmaceutical and medical products to patients and customers under a changed legal and regulatory environment as the EU medicine approval regime is now no longer recognized by the UK. In addition, Northern Ireland ("NI") remains aligned to EU regulatory frameworks. We continue to explore the ways in which the UK will be required to apply EU regulations in NI through discussions with the UK Government and relevant trade associations, as certain derogations expire at the end of 2021.

The agreement does not guarantee mutual recognition of professional and sector-specific qualifications which will restrict labour mobility, including, but limited to, pharmacists and nurses that we, or our customers, employ. The company celebrates its diverse workforce and recognises a number of its employees are non-UK nationals. The agreement, and how people react to it, may impact employee retention as well as future recruitment and raise costs. Effects on the workforce are expected to play out over a longer time period which will allow the business to react as appropriate.

The risk of fluctuations in exchange rates have the potential to cause business disruption and profitability impacts.

The company continues to seek advice and clarification from the Government regarding ongoing negotiations to enhance the trading agreement and mitigate the above risks. Mitigating actions have been implemented to secure supply and minimise business disruption.

Novel Coronavirus

On the 11th March 2020 the World Health Organisation declared novel coronavirus a pandemic. On the 23rd March 2020 the UK Government announced the first of several lockdown measures across the UK.

Our investments include Lloyds Pharmacy Limited and AAH Pharmaceuticals Limited provide a pivotal role in delivering healthcare services to communities around the country. The uncompromising priority of our investments are the safety of its employees and customers. The company reacted swiftly to the UK Government's advice to ensure safety measures were put in place and continues to follow its advice in order to remain open to patients as access to other healthcare (e.g. GPs, clinics and hospitals) has been restricted.

Metabolic Healthcare Limited, an investment Lloyds Pharmacy Limited made in fiscal 2020, saw significant growth throughout the pandemic in its mail order prescription service. Additionally, Lloyds Pharmacy rapidly expanded its online offering to ensure customers could safely continue to enjoy the products offered which included a new partnership between Lloyds Pharmacy Limited and Deliveroo announced in July 2020.

Whilst the future duration and impact of the novel coronavirus are unknown our investments will continue to support its communities whilst following the advice of the UK Government.

AAH Limited

Directors' Report *(continued)*

Year ended 31 March 2020

Events after the end of the reporting period

In March 2021, McKesson Europe AG extinguished £600 million of amounts owed to group undertakings due in 2035 in consideration for one ordinary share in Admenta UK Limited. In addition, McKesson Europe AG contributed £600 million in cash in exchange for one ordinary share in Admenta UK Limited.

The challenges of the Covid 19 pandemic continues to impact the business, although the directors believe that the long-term impact of this virus are difficult to predict.

AAH Limited

Directors' Report *(continued)*

Year ended 31 March 2020

Directors' responsibilities statement

The directors are responsible for preparing the Annual Report and the financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Accounting Standards, including Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" (United Kingdom Generally Accepted Accounting Practice). Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period.

In preparing these financial statements, the directors are required to:

- select suitable accounting policies and then apply them consistently;
- make judgments and accounting estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities. The directors are responsible for the maintenance and integrity of the corporate and financial information included on the company's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions

Auditor

Each of the persons who is a director at the date of approval of this report confirms that:

- so far as they are aware, there is no relevant audit information of which the company's auditor is unaware; and
- they have taken all steps that they ought to have taken as a director to make themselves aware of any relevant audit information and to establish that the company's auditor is aware of that information.

This confirmation is given and should be interpreted in accordance with the provisions of S418 of the Companies Act 2006.


The auditor is deemed to have been re-appointed in accordance with section 487 of the Companies Act 2006.

This report was approved by the board of directors on 2 June 2021 and signed on behalf of the board by:

C Keen
Director

Registered office:

Sapphire Court
Walsgrave Triangle
Coventry
CV2 2TX

DocuSigned by:

BDB7F99981984A8...

AAH Limited

Independent Auditor's Report to the Members of AAH Limited

Year ended 31 March 2020

Report on the audit of the financial statements

Opinion

In our opinion the financial statements of AAH Limited (the 'company'):

- give a true and fair view of the state of the company's affairs as at 31 March 2020 and of its loss for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice, including The Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland"; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

We have audited the financial statements which comprise:

- the statement of income and retained earnings;
- the statement of financial position; and
- the related notes 1 to 16.

The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" (United Kingdom Generally Accepted Accounting Practice).

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the auditor's responsibilities for the audit of the financial statements section of our report.

We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the Financial Reporting Council's (the 'FRC's') Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

We are required by ISAs (UK) to report in respect of the following matters where:

- the directors' use of the going concern basis of accounting in preparation of the financial statements is not appropriate; or
- the directors have not disclosed in the financial statements any identified material uncertainties that may cast significant doubt about the company's ability to continue to adopt the going concern basis of accounting for a period of at least twelve months from the date when the financial statements are authorised for issue.

We have nothing to report in respect of these matters.

AAH Limited

Independent Auditor's Report to the Members of AAH Limited *(continued)*

Year ended 31 March 2020

Other information

The directors are responsible for the other information. The other information comprises the information included in the annual report, other than the financial statements and our auditor's report thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in respect of these matters.

Responsibilities of directors

As explained more fully in the directors' responsibilities statement, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

A further description of our responsibilities for the audit of the financial statements is located on the FRC's website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor's report.

Report on other legal and regulatory requirements

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the strategic report and the directors' report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the strategic report and the directors' report have been prepared in accordance with applicable legal requirements.

In the light of the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified any material misstatements in the strategic report or the directors' report.

AAH Limited

Independent Auditor's Report to the Members of AAH Limited *(continued)*

Year ended 31 March 2020

Matters on which we are required to report by exception


Under the Companies Act 2006 we are required to report in respect of the following matters if, in our opinion:

- adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of directors' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit.

We have nothing to report in respect of these matters.

Use of our report

This report is made solely to the company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed.



Joanna Waring FCA (Senior Statutory Auditor)
For and on behalf of Deloitte LLP
Statutory Auditor
Birmingham, United Kingdom

Date: 02 June 2021

AAH Limited**Statement of Income and Retained Earnings****Year ended 31 March 2020**

	Note	2020 £000	2019 £000
Exceptional Item: Impairment of investments	9	<u>(56,167)</u>	<u>—</u>
Loss before taxation		(56,167)	—
Tax on result		<u>—</u>	<u>—</u>
Loss for the financial year and total comprehensive expense		<u>(56,167)</u>	<u>—</u>
Retained earnings at the start of the year		<u>4,778</u>	<u>4,778</u>
Retained (losses)/earnings at the end of the year		<u>(51,389)</u>	<u>4,778</u>


All the activities of the company are from continuing operations.

The notes on pages 11 to 19 form part of these financial statements.

AAH Limited**Statement of Financial Position****As at 31 March 2020**

	Note	2020 £000	2019 £000
Fixed assets			
Investments	9	–	56,167
Current assets			
Debtors	10	26,237	26,237
Net current assets		<u>26,237</u>	<u>26,237</u>
Total assets less current liabilities		<u>26,237</u>	<u>82,404</u>
Net assets		<u>26,237</u>	<u>82,404</u>
Capital and reserves			
Called up share capital	11	24,442	24,442
Share premium account	12	53,184	53,184
Profit and loss account	12	(51,389)	4,778
Shareholders' funds		<u>26,237</u>	<u>82,404</u>

These financial statements were approved by the board of directors and authorised for issue on 2 June 2021, and are signed on behalf of the board by:

DocuSigned by:

 BDB7F99981984A8...

C Keen
 Director

Company registration number: 00190705

The notes on pages 11 to 19 form part of these financial statements.

AAH Limited

Notes to the Financial Statements

Year ended 31 March 2020

1. General information

The company is a private company limited by shares, registered in England and Wales under Companies Act 2006. The address of the registered office is Sapphire Court, Walsgrave Triangle, Coventry, CV2 2TX. The principal activity of the Company is disclosed on page 1.

2. Statement of compliance

These financial statements have been prepared in compliance with FRS 102, 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland'.

3. Accounting policies

Basis of preparation

The financial statements have been prepared on a going concern basis which assumes the company will continue in existence for the foreseeable future.

The principal accounting policies are summarised below. They have all been applied consistently throughout the year and to the preceding period.

The financial statements have been prepared under the historical cost convention and in accordance with Financial Reporting Standard 102 (FRS 102) issued by the Financial Reporting Council.

The functional currency is considered to be pounds sterling because that is the currency of the primary economic environment in which the Company operates.

Consolidated financial statements

The financial statements contain information about AAH Limited as an individual company, rather than consolidated information as the parent of a group. The company is exempt under Section 400 of the Companies Act 2006 from the requirement to prepare group financial statements as the results of its subsidiary undertakings are included by full consolidation in the financial statements of its ultimate parent, McKesson Corporation, a company incorporated in North America.

Going concern

The directors have received confirmation from the ultimate parent company that intergroup debt will continue to be made available at levels sufficient to allow the company to meet its liabilities as they fall due for a period not less than 12 months. The directors have satisfied themselves that the ultimate parent company has the necessary financial resources to provide this support during this period, should it be required. Therefore, the directors have a reasonable expectation that the company has adequate resources internally and through its association with the McKesson Corp, to continue in operational existence for the foreseeable future. As such, the going concern basis has been adopted in preparing the annual report and financial statements.

Investments in group companies

Investments in group companies are shown at historic cost less any necessary write down for impairment. Such investments include both investments in shares issued by the subsidiary and other parent entity interests that in substance form part of the parent entity's investment in the subsidiary.

AAH Limited

Notes to the Financial Statements *(continued)*

Year ended 31 March 2020

3. Accounting policies *(continued)*

Disclosure exemptions

The entity satisfies the criteria of being a qualifying entity as defined in FRS 102. Its financial statements are consolidated into the financial statements of McKesson Corporation which can be obtained from McKesson Corporation, 6555 State Hwy 161, Irving, TX 75039, United States. As such, advantage has been taken of the following disclosure exemptions available under paragraph 1.12 of FRS 102:

- No cash flow statement has been presented for the company;
- Disclosures in respect of financial instruments have not been presented; and
- No disclosure has been given for the aggregate remuneration of key management personnel.

Income tax

The charge for taxation is based on the result for the period and takes into account taxation deferred because of timing differences between the treatment of certain items for accounting and taxation purposes. Deferred tax liabilities are provided in full but deferred tax assets are recognised only to the extent it is considered more likely than not that the associated tax deduction can be utilised on their reversal. Deferred tax liabilities and assets are not discounted.

Financial instruments

A financial asset or a financial liability is recognised only when the company becomes a party to the contractual provisions of the instrument.

Basic financial instruments are initially recognised at the transaction price, unless the arrangement constitutes a financing transaction, where it is recognised at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.

Debt instruments are subsequently measured at amortised cost.

Where investments in non-convertible preference shares and non-puttable ordinary shares or preference shares are publicly traded or their fair value can otherwise be measured reliably, the investment is subsequently measured at fair value with changes in fair value recognised in profit or loss. All other such investments are subsequently measured at cost less impairment.

Other financial instruments, including derivatives, are initially recognised at fair value, unless payment for an asset is deferred beyond normal business terms or financed at a rate of interest that is not a market rate, in which case the asset is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.

Other financial instruments are subsequently measured at fair value, with any changes recognised in profit or loss, with the exception of hedging instruments in a designated hedging relationship.

Financial assets that are measured at cost or amortised cost are reviewed for objective evidence of impairment at the end of each reporting date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss immediately.

For all equity instruments regardless of significance, and other financial assets that are individually significant, these are assessed individually for impairment. Other financial assets are either assessed individually or grouped on the basis of similar credit risk characteristics.

AAH Limited

Notes to the Financial Statements *(continued)*

Year ended 31 March 2020

3. Accounting policies *(continued)*

Financial instruments *(continued)*

Any reversals of impairment are recognised in profit or loss immediately, to the extent that the reversal does not result in a carrying amount of the financial asset that exceeds what the carrying amount would have been had the impairment not previously been recognised.

4. Critical accounting judgements and key sources of estimation uncertainty

In the application of the Company's accounting policies, which are described in note 3, the directors are required to make judgements, estimates and assumptions about the carrying amounts of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods.

The directors do not consider there to be any critical accounting judgements or key sources of estimation uncertainty

5. Auditor's remuneration

Auditor's remuneration for the audit of the company's annual financial statements of £4,000 (2019: £4,000) has been borne by Lloyds Pharmacy Limited, a fellow group company, and not recharged. No non-audit services have been provided by the auditor during the year (2019: £nil).

6. Particulars of employees

The company had no employees during the year, other than executive directors (2019: nil).

AAH Limited

Notes to the Financial Statements *(continued)*

Year ended 31 March 2020

7. Directors' emoluments

The emoluments of all directors are paid by a fellow subsidiary company, Lloyds Pharmacy Limited, which makes no recharge to the company. All other directors of this company are also directors of a number of fellow subsidiary companies and it is impossible to make an accurate apportionment of their emoluments in respect of each of these companies. Accordingly no emoluments in respect of these directors are disclosed. Their emoluments are included in the aggregate of directors' emoluments disclosed in the financial statements of Lloyds Pharmacy limited.

8. Tax on loss

Reconciliation of tax (income)/expense

The tax assessed on the loss for the year is lower than (2019: same as) the standard rate of corporation tax in the UK of 19% (2019: 19%).

	2020 £000	2019 £000
Loss before taxation	(56,167)	-
Loss by rate of tax	(10,671)	-
Adjustments in respect of prior periods	-	-
Non-deductible expenses	-	-
Impairment loss not deductible	10,671	-
Tax on loss	-	-

Factors that may affect future tax income

A change to the main UK corporation tax rate was announced in the Budget on 3 March 2021. Legislation will be introduced in Finance Bill 2021 to set the main rate at 25% for the year beginning 1 April 2023. The deferred tax rate applicable from 1 April 2020 is 19% (2019: 17%).

9. Investments

	Shares in group undertakings £000
Cost	
At 1 April 2019 and 31 March 2020	56,167
Impairment	
At 1 April 2019	-
Impairment losses	56,167
At 31 March 2020	56,167
Carrying amount	
At 31 March 2020	-
At 31 March 2019	56,167

Impairment charge of £56,167,000 is in respect of an investment in Admenta Holdings, the investment has been written down to Nil.

AAH Limited

Notes to the Financial Statements *(continued)*

Year ended 31 March 2020

9. Investments *(continued)*

Subsidiaries, associates and other investments

The directors believe that the carrying value of the investments is supported by their underlying net assets.

Principal subsidiaries and the nature of their businesses are as follows:

Subsidiary	Nature of business	Class of capital	% held
Admenta Holdings Limited	Investment holding company	£1 ordinary shares	100
AAH Pharmaceuticals Limited *	Healthcare services	£1 ordinary shares	100
Barclay Pharmaceuticals Limited *	Wholesale distribution	£1 ordinary shares	100
Lloyds Pharmacy Limited *	Retail pharmacies	£1 ordinary shares	100

* Held indirectly through other subsidiaries

A full list of all investments, direct and indirect, is included in note 15. All investments are in UK companies and have the same registered address as AAH Limited. The only exceptions to this are listed in the table below.

Name	Registered office
Stephen Smith Limited	PO Box 25, Regency Court, Gategny Esplanade, St Peter Port, Guernsey, GY1 3AP
GJ Maley Limited	22 Woodbourne Road, Douglas, Isle of Man, IM1 3AL
AAH Lloyds Insurance (IOM) Limited	Third Floor, St George's Court, Upper Church Street, Douglas, IM1 1EE, Isle of Man
Savory & Moore (Jersey) Limited	PO Box 301, 40 Esplanade, St Helier, Jersey, JE4 8UG
My MHealth Limited	161 8 Trinity, 161 Old Christchurch Road, Bournemouth, England, BH1 1JU

10. Debtors

	2020	2019
	£000	£000
Amounts owed by subsidiary	<u>26,237</u>	<u>26,237</u>

The amounts due from other group undertakings are payable on demand and represent interest free loans.

AAH Limited**Notes to the Financial Statements** *(continued)***Year ended 31 March 2020****11. Called up share capital****Authorised share capital**

	2020		2019	
	No.	£000	No.	£000
Ordinary shares of £0.25 each	<u>111,000,000</u>	<u>27,750</u>	<u>111,000,000</u>	<u>27,750</u>

Issued, called up and fully paid

	2020		2019	
	No.	£000	No.	£000
Ordinary shares of £0.25 each	<u>97,769,868</u>	<u>24,442</u>	<u>97,769,868</u>	<u>24,442</u>

12. Reserves

Share premium account - This reserve records the amount above the nominal value received for shares sold, less transaction costs.

Profit and loss account - This reserve records retained earnings and accumulated losses.

13. Related party transactions

The company has not disclosed transactions with fellow group companies which are 100% owned, in accordance with the exemption under the terms of FRS 102.33.1A - "Related party disclosures".

14. Controlling party

The immediate parent undertaking is Admenta UK Limited.

The ultimate parent undertaking and controlling party of the Company is McKesson Corporation, a company registered in North America.

Consolidated financial statements for the largest group of undertakings are prepared by McKesson Corporation and may be obtained from its registered address at McKesson Corporation, 6555 State Hwy 161, Irving, TX 75039, United States.

Consolidated financial statements for the smallest group of companies are prepared by McKesson Europe AG and may be obtained from its registered address at McKesson Europe AG, Stockholmer Platz 1, 70173 Stuttgart, Germany.

AAH Limited

Notes to the Financial Statements *(continued)*

Year ended 31 March 2020

15. Other investments

Subsidiary	Country of Registration	Class of capital	% held
2012 Dream Limited	Dormant company	£1 Ordinary shares	100
28CVR Limited		£0.10 Ordinary and A	
	Holding company	Ordinary shares	100
30MC Limited	Dormant company	£1 Ordinary shares	100
5AAH Glass & Windows Limited	Dormant company	£1 Ordinary shares	100
A C Ferguson (Chemist) Limited	Dormant company	£1 Ordinary shares	100
A Miller (Chemist) Limited	Dormant company	£1 Ordinary shares	100
A. Suthrell (Haulage) Limited	Dormant company	£1 Ordinary shares	100
AAH Builders Suppliers Limited	Dormant company	£1 Ordinary shares	100
AAH Furb Pension Trustee Limited	Dormant company	£1 Ordinary shares	100
AAH Lloyds Insurance (IOM) Limited	Insurance company	£1 Ordinary shares	100
AAH Lloyds Pension Trustees Limited	Dormant company	£1 Ordinary shares	100
AAH Lloyds Pension Trustees Limited	Dormant company	£1 Ordinary shares	100
AAH Nominees Limited	Dormant company	£1 Ordinary shares	100
AAH One Limited	Dormant company	£1 Ordinary shares	100
AAH Pharmaceuticals Limited	Healthcare services	£1 Ordinary shares	100
AAH Twenty Four Limited	Dormant company	£1 Ordinary shares	100
AAH Twenty Limited	Dormant company	£1 Ordinary shares	100
Acme Drug Company Limited	Dormant company	£1 Ordinary shares	100
Added Marketing Limited	Dormant company	£1 Ordinary shares	100
Admenta Holdings Limited (*)	Holding company	£1 Ordinary shares	100
Admenta Pension Trustees Limited	Dormant company	£1 Ordinary shares	100
AHLP Pharmacy Limited	Retail pharmacy	£1 A Ordinary shares	75
Baillieston Health Centre Pharmacy Limited	Health centre	£1 Ordinary shares	64
Barclay Pharmaceuticals Limited	Wholesale distribution	£1 Ordinary shares	100
Barry Shooter (Romford) Limited	Dormant company	£1 Ordinary shares	100
Berkshire Medical Supplies Limited	Dormant company	£1 Ordinary shares	100
Betterlifehealthcare Limited		£1 Ordinary A shares and	
	Online retailer	£1 Ordinary B shares	100
Big Pharma Limited	Dormant company	£1 Ordinary shares	100
Blakey And Griffin Limited	Dormant company	£1 Ordinary shares	100
Brian Corps (Chemist) Limited	Dormant company	£1 Ordinary shares	100
Bridport Medical Centre Services Limited	Dormant company	£1 Ordinary shares	100
Caronet Trading Limited	Dormant company	£1 Ordinary shares	100
Clark Munro Limited	Dormant company	£1 Ordinary shares	100
Clarke Care Group Limited	Dormant company	£1 Ordinary shares	100
Company Chemists Association Limited	Trade association	£1 Ordinary shares	27
D.F. Brint (Portishead) Limited	Dormant company	£1 Ordinary shares	100
David J. Thomas Limited	Dormant company	£1 Ordinary shares	100
Eclipse Healthcare Limited	Dormant company	£1 Ordinary shares	100
Escon (St Neots) Limited	Dormant company	£1 Ordinary shares	100
Evolution Homecare Services Limited	Healthcare services	£1 Ordinary shares	100
Expert Health Limited	Online Health	£1 Ordinary shares	100
Farillon Limited	Dormant company	£1 Ordinary shares	100
Firth & Pilling Limited	Dormant company	£1 Ordinary shares	100
Foster & Plumpton Group Limited	Dormant company	£1 Ordinary shares	100
Foster & Plumpton Limited	Dormant company	£1 Ordinary shares	100
G J Maley Limited	Retail pharmacies	£1 Ordinary shares	100
Gordons Pharmacy Limited	Dormant company	£1 Ordinary shares	100
GPL 2007 Limited	Dormant company	£1 Ordinary shares	100
Graeme Pharmacy (Stirling) Limited	Dormant company	£1 Ordinary shares	100

AAH Limited

Notes to the Financial Statements *(continued)*

Year ended 31 March 2020

HE Niblett Limited	Dormant company	£1 Ordinary shares	100
Health Needs Limited	Dormant company	£1 Ordinary shares	100
Healthclass Limited	Dormant company	£1 Ordinary shares	100
Herbert Ferryman Limited	Dormant company	£0.10 Ordinary shares	100
Hill-Smith (Warrington) Limited	Dormant company	£1 Ordinary shares	100
Houghton And Lappin Limited	Dormant company	£1 Ordinary shares	100
Hywel Davies (Caerphilly) Limited	Dormant company	£1 Ordinary shares	100
Independent Pharmacy Care Centres (2008) Limited	Dormant company	£1 Ordinary shares	100
Inspiron Distribution Limited	Dormant company	£1 Ordinary shares	100
IPCC Limited	Dormant company	£1 Ordinary shares	100
J S Dent Limited	Dormant company	£1 Ordinary shares	100
John Bell & Croyden Limited	Retail pharmacy	£0.25 Ordinary shares	100
John Hamilton (Pharmaceuticals) Limited	Dormant company	£1 Ordinary shares	100
John Robertson Butler & Son Limited	Dormant company	£1 Ordinary shares	100
Levelcrown Limited	Dormant company	£1 Ordinary shares	100
Livingston Health Centre (P.D) Co. Limited	Dormant company	£0.01 Ordinary shares	100
Lloyds Pharmacy Clinical Homecare Limited	Healthcare Services	£1 Ordinary Shares	100
Lloyds Pharmacy Limited	Retail pharmacies	£1 Ordinary shares	100
Lloyds Properties Limited	Property services	£1 Ordinary shares	100
Lloyds Retail Chemists Limited	Dormant company	£1 Ordinary shares	100
LPL One Limited	Dormant company	£1 Ordinary shares	100
M H Gill Limited	Dormant company	£1 Ordinary shares	100
M J F Limited	Dormant company	£1 Ordinary shares	100
M. & M.L. Grundy Limited	Dormant company	£1 Ordinary shares	100
MASTA Limited	Traveller Health Services	£1 Ordinary Shares	100
Medimart Limited	Dormant company	£1 Ordinary shares	100
Metabolic Healthcare Holdings Limited	Retail pharmacy	£0.0001 Ordinary Shares	100
Metabolic Healthcare Limited	Retail pharmacy	£1 Ordinary Shares	100
Mount Pharmacy Limited	Dormant company	£1 Ordinary shares	100
Munro Pharmacy Limited	Dormant company	£1 Ordinary shares	100
MyMHealth Limited	Online healthcare	£0.001 Ordinary Shares	8
Newkirk Pharmacy Limited	Dormant company	£1 Ordinary shares	100
Optimed Health Limited	Consulting	£1 Ordinary Shares	100
Palemoda Limited	Dormant company	£1 Ordinary shares	100
Paul Wheeler Limited	Dormant company	£1 Ordinary shares	100
Peel Street Pharmacy Limited	Dormant company	£1 Ordinary shares	100
Pharmagen Limited	Wholesale services	£1 Ordinary shares	100
Prescribing Support Services Limited	Consulting	£1 Ordinary Shares	100
Primelight Limited	Dormant company	£1 Ordinary shares	100
R.F Foskett & Son Limited	Dormant company	£1 Ordinary shares	100
Sangers (Northern Ireland) Limited	Wholesale Distribution	£1 Ordinary Shares	100
Savory & Moore (Jersey) Limited	Retail pharmacies	£1 Ordinary shares	90
Scholes (Chemist) Limited	Dormant company	£1 Ordinary shares	100
Statim Finance Limited	Dormant company	£1 Ordinary shares	100
Stephen Smith Limited	Retail pharmacies	£1 Ordinary shares	57
Superfield Limited	Dormant company	£1 Ordinary shares	100
T And I White Limited	Dormant company	£1 Ordinary shares	100
Thurnby Rose Limited	Dormant company	£1 Ordinary shares	100

AAH Limited

Notes to the Financial Statements *(continued)*

Year ended 31 March 2020

Uscita Limited	Dormant company	£1 Ordinary shares	100
W. Jamieson (Chemists) Limited	Dormant company	£1 Ordinary shares	100
W.H.Chanter Limited	Dormant company	£1 Ordinary shares	100
Westclose Limited	Dormant company	£1 Ordinary shares	100
Woodside Pharmacy (Glasgow) Limited	Retail pharmacy	£0.25 Ordinary shares	100

(*) denotes a direct investment held by AAH Limited. All other listed investments are indirect investments of AAH Limited.

16. Events after the reporting period

In March 2021, McKesson Europe AG extinguished £600 million of amounts owed to group undertakings due in 2035 in consideration for one ordinary share in Admenta UK Limited. In addition, McKesson Europe AG contributed £600 million in cash in exchange for one ordinary share in Admenta UK Limited.

The challenges of the Covid 19 pandemic continues to impact the business, although the directors believe that the long-term impact of this virus are difficult to predict.